Biological Product Suffix Submissions Limited To 10 Candidates By US FDA
Executive Summary
Increasing cap on number suffixs that sponsors can submit from three to 10 will increase review efficiency, agency says, but evaluation will still stop after finding first acceptable suffix as part of final guidance on distinguishable nonproprietary names for novel biological products and biosimilars.
You may also be interested in...
Suffix Smackdown: Gottlieb Calls Issue 'Red Herring' For Biosimilars
'This is important for our own pharmacovigilance,' US FDA commissioner says. 'We still have an open question on whether or not we’re going to apply a suffix or change also the branded company’s name as well.'
Suffix Smackdown: Gottlieb Calls Issue 'Red Herring' For Biosimilars
'This is important for our own pharmacovigilance,' US FDA commissioner says. 'We still have an open question on whether or not we’re going to apply a suffix or change also the branded company’s name as well.'
First Three Novel Biologic Suffixes Came Courtesy Of US FDA, Not Sponsors
FDA assigned a four-letter nonproprietary name suffix to Genentech's Hemlibra because an expedited review left little time to evaluate the sponsor's late-submitted proposals; UltraGenyx asked FDA to assign one for Mepsevii, while Spark submitted 10 suffix candidates for Luxturna only to see all of them rejected for being too meaningful.